GlassScriptPhysician profile
Danielle Vesth
NPI 1881245371
$2,666.28
in general payments reported to CMS, 2019-2025
13 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $1,157 · 2023: $660 · 2024: $168 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.43 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $906.64 | 2022 | |
| Tactile Systems Technology INC | $817.68 | 2021-2023 | Entre Plus, Flexitouch Plus |
| W. L. Gore & Associates, INC. | $314.48 | 2021-2023 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Conformable Thoracic Endoprosthesis |
| Lemaitre Vascular, INC. | $153.67 | 2024 | Artegraft Vascular Graft |
| Medtronic, INC. | $126.07 | 2021-2023 | Venaseal |
| Terumo Medical Corporation | $115.17 | 2023 | Azur Cx Detachable |
| Orthalign INC | $82.99 | 2025 | Orthalign Plus |
| Impulse Dynamics (USA) INC. | $55.70 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $31.87 | 2022-2023 | Xarelto |
| Bioventus LLC | $18.07 | 2025 | Durolane |
| Endologix LLC | $17.39 | 2021 | |
| Organogenesis INC. | $13.86 | 2024 | Cygnus Dual |
| Aesculap, INC. | $12.69 | 2023 | No Applicable Marketed Product Name |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Vesth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.